Revance Therapeutics Inc (RVNC)
3.81
-0.03
(-0.78%)
USD |
NASDAQ |
Nov 22, 14:52
Revance Therapeutics Enterprise Value: 649.94M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 649.94M |
| November 20, 2024 | 645.74M |
| November 19, 2024 | 641.55M |
| November 18, 2024 | 665.68M |
| November 15, 2024 | 684.56M |
| November 14, 2024 | 699.24M |
| November 13, 2024 | 691.90M |
| November 12, 2024 | 680.36M |
| November 11, 2024 | 609.03M |
| November 08, 2024 | 635.25M |
| November 07, 2024 | 853.45M |
| November 06, 2024 | 856.60M |
| November 05, 2024 | 859.74M |
| November 04, 2024 | 856.60M |
| November 01, 2024 | 855.55M |
| October 31, 2024 | 866.04M |
| October 30, 2024 | 868.10M |
| October 29, 2024 | 867.05M |
| October 28, 2024 | 866.00M |
| October 25, 2024 | 740.12M |
| October 24, 2024 | 803.06M |
| October 23, 2024 | 802.01M |
| October 22, 2024 | 802.01M |
| October 21, 2024 | 800.96M |
| October 18, 2024 | 802.01M |
| Date | Value |
|---|---|
| October 17, 2024 | 790.47M |
| October 16, 2024 | 800.96M |
| October 15, 2024 | 792.57M |
| October 14, 2024 | 786.28M |
| October 11, 2024 | 800.96M |
| October 10, 2024 | 798.87M |
| October 09, 2024 | 796.77M |
| October 08, 2024 | 794.67M |
| October 07, 2024 | 806.21M |
| October 04, 2024 | 794.67M |
| October 03, 2024 | 798.87M |
| October 02, 2024 | 791.52M |
| October 01, 2024 | 792.57M |
| September 30, 2024 | 791.52M |
| September 27, 2024 | 756.75M |
| September 26, 2024 | 759.87M |
| September 25, 2024 | 750.50M |
| September 24, 2024 | 770.81M |
| September 23, 2024 | 757.27M |
| September 20, 2024 | 803.63M |
| September 19, 2024 | 807.80M |
| September 18, 2024 | 822.38M |
| September 17, 2024 | 819.78M |
| September 16, 2024 | 820.30M |
| September 13, 2024 | 880.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
378.57M
Minimum
Apr 01 2020
3.267B
Maximum
May 09 2023
1.390B
Average
1.287B
Median
Aug 11 2020
Enterprise Value Benchmarks
| Recursion Pharmaceuticals Inc | 1.249B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| MEI Pharma Inc | -8.182M |
| GlycoMimetics Inc | 6.243M |
| Anebulo Pharmaceuticals Inc | 37.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.12M |
| Revenue (Quarterly) | 59.88M |
| Total Expenses (Quarterly) | 92.14M |
| EPS Diluted (Quarterly) | -0.37 |
| Gross Profit Margin (Quarterly) | 70.55% |
| Profit Margin (Quarterly) | -63.65% |
| Earnings Yield | -50.92% |
| Normalized Earnings Yield | -88.18 |